The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly improved kidney function and cardiovascular outcomes in patients with obesity and heart failure with preserved ejection fraction (HFpEF), compared with placebo after one year. These findings were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and [...]from SciTechDaily https://ift.tt/AI7JGRa
